Fig. 7

Cytotoxic effects of the novel tribodies or the combinations of Tb535H with the parental mAbs on MDA-MB-231 cells co-cultured with hPBMCs. Breast MDA-MB-231 tumor cells were co-cultured with hPBMCs (Effector:Target cells ratio 5:1) and treated for 48 h with (A) 53L1 and 53L10 (striped bars), (B) 53D (striped bars), (C) 53G (striped bars). Tb535H (light grey bars), parental immunomodulatory mAbs (dark grey bars) or their combinations (black bars) were also tested at the indicated concentrations. Co-cultures untreated or treated with the unrelated Palivizumab-derived tribody 53P (C, empty bars) were used as negative controls. Cell lysis was measured by detecting LDH release, as described in Methods. Error bars depict means ± SD. P-values for the indicated compounds are: *** P ≤ 0,001; ** P < 0.01; * P < 0.05 by student’s t-test (two variables)